Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semorinemab (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms TAURIEL
  • Sponsors Genentech

    • Most Recent Events

    • 20 Jul 2023 Results from CREAD, CREAD2 and Tauriel; assessing assess the additive prognostic value of including baseline [18F]GTP1 tau-PET with the other common predictors presented at the Alzheimer's Association International Conference 2023.
    • 09 Nov 2022 Results from CREAD, CREAD2 and Tauriel; assessing independence in activities of daily living in People With Early Alzheimers Disease, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 04 Aug 2022 Results of evaluation of Longitudinal [18F]GTP1 Tau Burden Metrics, presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top